WaveMan
WaveMan · Company
CVRX · Cvrx, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CVRX CVRx (CVRX) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001235912
Quote by TradingView
Activist 13DC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
44
13F, latest reported quarter

What the filings say about CVRX

Insiders, 180 days
+$73.1K net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Activist stakes (13D), 180 days
1 filing
Largest: 5.5% of the class

CVRx insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CVRx, Inc. insiders bought a net $73.1K of stock across 62 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Binkowski Brent
CHIEF OPERATING OFFICER
BUY
2026-08-13 SEC
26,223
$76.4K
-52.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 12, 2026.
  • The trade is 46.4% of the 56,514 shares held after it.
  • No other insider bought within 30 days.
  • 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF OPERATING OFFICER Binkowski Brent bought about $76.4K of CVRX on Aug 13, 2026; 44 funds added in the latest 13F quarter.
Binkowski Brent
CHIEF OPERATING OFFICER
SELL
2026-08-13 SECtraded 2026-08-12
1,309
$3.3K
-52.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 4.3% of the 30,291 shares held after it.
  • No other insider sold within 30 days.
  • 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF OPERATING OFFICER Binkowski Brent sold about $3.3K of CVRX on Aug 12, 2026; 44 funds added in the latest 13F quarter.
Adamson Philip B.
Chief Medical Officer
SELL
2026-03-16 SECtraded 2026-03-02
1,262
$10.0K
-82.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.0% of the 61,578 shares held after it.
  • 4 other insiders sold within 30 days.
  • 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Adamson Philip B. sold about $10.0K of CVRX on Mar 2, 2026; 4 other insiders sold within 30 days and 44 funds added in the latest 13F quarter.
Hykes Kevin
PRES & CEO
SELL
2026-03-03 SECtraded 2026-03-02
7,763
$61.3K
-82.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 12, 2025.
  • +68.0% median (+68.0% mean) 90-day return after 2 previous buys.
  • The trade is 2.7% of the 284,237 shares held after it.
  • 4 other insiders sold within 30 days.
  • 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRES & CEO Hykes Kevin sold about $61.3K of CVRX on Mar 2, 2026; 4 other insiders sold within 30 days and 44 funds added in the latest 13F quarter.
VERRASTRO PAUL
CHIEF MKTG & STRAT OFFICER
SELL
2026-03-03 SECtraded 2026-03-02
1,284
$10.1K
-82.9%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Nov 19, 2024.
  • The trade is 2.1% of the 60,551 shares held after it.
  • 4 other insiders sold within 30 days.
  • 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MKTG & STRAT OFFICER VERRASTRO PAUL sold about $10.1K of CVRX on Mar 2, 2026; 4 other insiders sold within 30 days and 44 funds added in the latest 13F quarter.
62 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 57 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$73.1K over 180 days
+$73.1K over 90 days
more than 71% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
44 funds bought in last quarter
below 61% of Medical Devices
Revenue
+10.4% year over year
more than 51% of Medical Devices
Margin
-94.1% net margin
below 80% of Medical Devices
Buybacks
no share repurchases reported
Short interest
11.7% of the float short (float per yahoo 2026-10-27) · 3.1 days to cover · settled 2026-10-15
more than 80% of Medical Devices
The situation: each line is one rule over one dataset
Chernett Jorey disclosed a 5%+ stake (5.5%) in the last six months.
3 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CVRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-85.6%12M
-87%-56%-24%+7%2025-102025-122026-022026-042026-062026-082026-10 2025-11-06 · Johnson & Johnson Innovation - JJDC, Inc. sold $534.3K2026-02-20 · Jain Mudit K. bought $297.6K2025-11-25 · Johnson & Johnson Innovation - JJDC, Inc. sold $160.5K2026-08-13 · Binkowski Brent bought $76.4K2025-11-26 · Johnson & Johnson Innovation - JJDC, Inc. sold $63.6K2025-11-26 · JOHNSON & JOHNSON sold $63.6K2026-03-02 · Hykes Kevin sold $61.3K2026-03-02 · John Robert Allen sold $31.3K2025-11-24 · JOHNSON & JOHNSON sold $22.1K2026-03-02 · OASHEIM JARED sold $13.8K2026-03-02 · VERRASTRO PAUL sold $10.1K2025-11-12 · JOHNSON & JOHNSON sold $10.0K2026-03-02 · Adamson Philip B. sold $10.0K2025-11-21 · JOHNSON & JOHNSON sold $5.0K2026-08-12 · Binkowski Brent sold $3.3K2026-02-18 · Jain Mudit K. bought $2.8K2025-11-07 · Johnson & Johnson Innovation - JJDC, Inc. sold $2.0K2026-08-24 · Chernett Jorey filed a 5%+ stake (5.5%)
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CVRX: institutional holders (13F)

13F holdings, latest reported quarter
JOHNSON & JOHNSON
4,024,861 sh
$20.7M
NEA Management Company, LLC
1,954,440 sh
$10.0M
BlackRock, Inc.
1,245,459 sh
$6.4M
ROYAL BANK OF CANADA
1,233,212 sh
$6.3M
GSK plc
1,007,583 sh
$5.2M

Congress trades in CVRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Chernett Jorey
Activist 13D · 2026-08-24
5.5%

CVRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CVRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$187.6K position · as of 2026-06-30
0.1%
GuideMark Small/Mid Cap Core Fund
$32.0K position · as of 2026-06-30
0.0%
Goldman Sachs Small Cap Growth Insights Fund
$93.1K position · as of 2026-07-31
0.0%
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund
$56.4K position · as of 2026-06-30
0.0%
NVIT GS Small Cap Equity Insights Fund
$47.6K position · as of 2026-06-30
0.0%
U.S. Small Cap Equity Fund
$170.4K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
10 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
10
Not applicable
4 active
What changed recently
BAROSTIM THERAPY™ In Resistant Hypertension
2026-09-12 · Completion moved 2024-07 → 2027-07
,
BAROSTIM THERAPY™ In Resistant Hypertension
2026-09-12 · Unknown → Recruiting
,
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
2026-09-12 · Completion moved 2024-07 → 2025-11-03
,
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
2026-09-12 · Unknown → Completed
,
BAROSTIM NEO Hypertension Pivotal Trial
2026-09-12 · Suspended → Completed
Not applicable
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
2026-09-12 · Completion moved 2024-07 → 2027-07
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $73.1K bought by insiders over 180 days, 44 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

CVRX financials

Revenue growth
+10.4%
XBRL, annual
Net margin
-94.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$61.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-84.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$41.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
3.10x
long-term 2026-06-30 plus current 2021-09-30 (57 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.65x
TTM operating cash flow over long-term 2026-06-30 plus current 2021-09-30 (57 months older than the period end)
Return on equity
-133.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-49.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-50.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$35.9M
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2021-09-30 (57 months older than the period end), minus cash 2026-06-30
FCF yield
-106.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$56.7M$51.3M$39.3M$22.5M
Gross profit$48.3M$43.0M$33.0M$17.5M
Operating income-$51.3M-$59.5M-$43.1M-$42.5M
Net income-$53.3M-$60.0M-$41.2M-$41.4M
EPS (diluted)-2.04-2.65-1.99-2.02
Operating cash flow-$40.2M-$39.1M-$39.0M-$42.7M
Cash$75.7M$105.9M$90.6M$106.2M
Long-term debt$49.5M$49.3M$29.2M$6.7M
SEC XBRL, fiscal years, as known on 2026-10-28

CVRX Stock Sonar score 6/7 axes

Find similar shapesCompare

CVRX ranks highest on risk and compliance (63rd percentile) and insider conviction (61st), and lowest on financial health (24th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
28
Inputs
  • Return on equity-133.4% · 21 pct, sector of 183
  • Return on assets-49.1% · 31 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-50.9% · 32 pct, sector of 188
Financial health
24
Inputs
  • Debt to equity3.10x · 10 pct, sector of 159
  • Cash flow to debt-0.65x · 38 pct, sector of 150
Growth
51
Inputs
  • Revenue growth, YoY+10.4% · 51 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
61
Inputs
  • Net Form 4 buying (codes P and S), 180d$73K · 71 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
39
Inputs
  • Funds adding, latest quarter44 · 39 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
63
Inputs
  • Short interest, % of float+11.7% · 15 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+6.2% · 75 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CVRX filings, in plain words

Are CVRx insiders buying or selling CVRX?

In the 180 days to 2026-10-28, CVRx insiders were net buyers, a net $73.1K: $76.4K of purchases and $3.3K of sales reported on Form 4, by 1 buyer and 1 seller.

Read the full summary

In the 180 days to 2026-10-28, CVRx insiders were net buyers of CVRX, a net $73.1K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Purchases outweighed sales more than tenfold by value. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 5.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies